Avadel Pharmaceuticals to Present at Upcoming Investor Conferences in November

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced CEO Greg Divis's participation in two upcoming investor conferences in November 2021:

• Stifel’s 2021 Virtual Healthcare Conference on November 16 at 8:00 a.m. E.T.
• Jefferies London Healthcare Conference available on demand starting November 18 at 3:00 a.m. E.T.

A webcast and archived recordings will be on Avadel's Investor Relations website for 90 days post-conference. Avadel focuses on innovative medications, notably the investigational drug candidate FT218 for treating narcolepsy.

DUBLIN, Ireland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences in November:

• Stifel’s 2021 Virtual Healthcare Conference: Fireside chat on Tuesday, November 16 at 8:00 a.m. E.T.
• Jefferies London Healthcare Conference: Fireside chat available for on demand viewing starting on Thursday, November 18 at 3:00 a.m. E.T.

A webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292

FAQ

What is Avadel Pharmaceuticals announcing regarding investor conferences in November 2021?

Avadel Pharmaceuticals is announcing CEO Greg Divis's participation in Stifel’s 2021 Virtual Healthcare Conference and Jefferies London Healthcare Conference.

When is the Stifel's 2021 Virtual Healthcare Conference?

The Stifel’s 2021 Virtual Healthcare Conference will take place on November 16, 2021, at 8:00 a.m. E.T.

How can I watch Avadel Pharmaceuticals' investor conference presentations?

Webcasts of the investor conferences will be available on Avadel's Investor Relations website for 90 days after each event.

What is the focus of Avadel Pharmaceuticals' lead drug candidate FT218?

FT218 is designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.

When will the Jefferies London Healthcare Conference presentation be available?

The Jefferies London Healthcare Conference presentation will be available for on-demand viewing starting on November 18, 2021, at 3:00 a.m. E.T.